Drugs / Engerix-BTM
last change Feb 2012 re-read 2 minutes ago

Engerix-BTM

also known as Engerix-B
Developed for
human papilloma virus infection

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01277042 Comparator Feb → Sep 2011 human papilloma virus infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Engerix-BTM ClinicalTrials.gov intervention name — accepted as the source's own label NCT01277042
Known as Engerix-B “Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.” NCT01277042
Route Intramuscular “Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.” NCT01277042